Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.

Filicori M, Flamigni C, Cognigni G, Dellai P, Arnone R, Falbo A, Capelli M

The Journal of clinical endocrinology and metabolism1 Jul 1993Cited by 22 (Europe PMC)

PMID8325935DOI10.1210/jcem.77.1.8325935PepBankPUB-08325935

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In women, FSH tended to be higher with depot triptorelin than with buserelin, without reported statistical significance for triptorelin.
In plain wordsIn women, FSH tended to be higher with depot triptorelin than with buserelin, without reported statistical significance for triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFSH in treatment month three
Study
n = 20
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).
Source sentences
Summary
Conversely, FSH levels in the third month of treatment tended to be higher in the depot GnRH-A groups than in group B, and this difference achieved statistical significance (P < 0.05) in groups G and L during test C.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
and triptorelin (group T; 3.75 mg, im, every 28 days).
Report a problemFND-0832593502
02HumanNon-randomized trialEfficacy outcome
In normally cycling women, FSH was higher with goserelin than with buserelin during test C in the third treatment month (P < 0.05).
In plain wordsIn normally cycling women, FSH was higher with goserelin than with buserelin during test C in the third treatment month.
Peptide
Goserelin
Outcome
IncreaseFSH during GnRH test C
Study
n = 20
Comparator
Buserelin 300 micrograms subcutaneously every 12 hours
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · subcutaneous · 3 monthsAs given in this study (human).
Measurements
P value
< 0.05
FSH: goserelin versus buserelin during test C
Source sentences
Summary
Conversely, FSH levels in the third month of treatment tended to be higher in the depot GnRH-A groups than in group B, and this difference achieved statistical significance (P < 0.05) in groups G and L during test C.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
goserelin (group G; 3.6 mg, sc, every 28 days)
Report a problemFND-0832593506
03HumanNon-randomized trialEfficacy outcome
In normally cycling women at test B, two goserelin recipients had individual estradiol above 75 pmol/L, whereas the mean estradiol level in the buserelin group was below 75 pmol/L.
In plain wordsAt test B, two women receiving goserelin had estradiol above 75 pmol/L, whereas the average level in the buserelin group was below 75 pmol/L.
Peptide
Goserelin
Outcome
Not applicableEstradiol above suppression threshold during GnRH test B
Study
n = 20
Comparator
Buserelin 300 micrograms subcutaneously every 12 hours
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · subcutaneous · 57 daysAs given in this study (human).
Measurements
Patients with estradiol above 75 pmol/L
2 patients
goserelin, test B
Estradiol threshold
75 pmol/L
test B
Source sentences
Summary
In GnRH test B, while the mean estradiol (E2) level was less than 75 pmol/L (< 20 pg/mL) in all group B subjects, individual E2 levels were greater than 75 pmol/L in five patients receiving depot GnRH-A (two in group G, one in L, and two in T).
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
GnRH tests (100 micrograms, iv) were performed before treatment (cycle day 7; test A) and on treatment days 57 (i.e. 1 day after the third depot GnRH-A; test B) and 84 (i.e. 28 days after the third depot GnRH-A; test C).
Report a problemFND-0832593507
04HumanNon-randomized trialEfficacy outcome
In normally cycling women with male-related infertility or benign reproductive disorders, leuprorelin produced significantly higher FSH than buserelin during test C in the third treatment month.
In plain wordsIn normally cycling women with male-related infertility or benign reproductive disorders, FSH was significantly higher with leuprorelin than with buserelin during test C.
Peptide
Leuprolide
Outcome
IncreaseFSH during test C
Study
n = 20
Comparator
Buserelin 300 micrograms subcutaneously every 12 hours
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).
Measurements
P value
< 0.05
leuprorelin versus buserelin during test C
Source sentences
Summary
Conversely, FSH levels in the third month of treatment tended to be higher in the depot GnRH-A groups than in group B, and this difference achieved statistical significance (P < 0.05) in groups G and L during test C.
3 context sentences(design, population, supporting numbers)
Summary · context
GnRH tests (100 micrograms, iv) were performed before treatment (cycle day 7; test A) and on treatment days 57 (i.e. 1 day after the third depot GnRH-A; test B) and 84 (i.e. 28 days after the third depot GnRH-A; test C).
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
leuprorelin (group L; 3.75 mg, im, every 28 days),
Report a problemFND-0832593510
05HumanNon-randomized trialEfficacy outcome
In women receiving triptorelin, two patients had estradiol above 75 pmol/L during GnRH test B.
In plain wordsIn women receiving triptorelin, two patients had estradiol above 75 pmol/L during GnRH test B.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableEstradiol above threshold at test B
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).
Measurements
Patients with estradiol above 75 pmol/L
2 patients
triptorelin group, GnRH test B
Source sentences
Summary
In GnRH test B, while the mean estradiol (E2) level was less than 75 pmol/L (< 20 pg/mL) in all group B subjects, individual E2 levels were greater than 75 pmol/L in five patients receiving depot GnRH-A (two in group G, one in L, and two in T).
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
and triptorelin (group T; 3.75 mg, im, every 28 days).
Report a problemFND-0832593503
06HumanNon-randomized trialEfficacy outcome
In women receiving triptorelin, no estradiol values above 75 pmol/L were reported during test C.
In plain wordsIn women receiving triptorelin, no estradiol values above 75 pmol/L were reported during test C.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableEstradiol above threshold at test C
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg every 28 days · intramuscular · 3 monthsAs given in this study (human).
Source sentences
Summary
Finally, individual E2 levels during test C were greater than 75 pmol/L in only two patients of group G, who also reported vaginal spotting.
3 context sentences(design, population, supporting numbers)
Summary · context
In GnRH test B, while the mean estradiol (E2) level was less than 75 pmol/L (< 20 pg/mL) in all group B subjects, individual E2 levels were greater than 75 pmol/L in five patients receiving depot GnRH-A (two in group G, one in L, and two in T).
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
and triptorelin (group T; 3.75 mg, im, every 28 days).
Report a problemFND-0832593504
07HumanNon-randomized trialEfficacy outcome
In normally cycling women, goserelin profoundly suppressed the immunoreactive LH response to GnRH during treatment, as did all tested analogs.
In plain wordsIn normally cycling women, goserelin profoundly suppressed the LH response to GnRH during treatment, as did all tested analogs.
Peptide
Goserelin
Outcome
DecreaseImmunoreactive LH response to GnRH
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Profound suppression of the iLH response to the GnRH test occurred in all subjects during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
goserelin (group G; 3.6 mg, sc, every 28 days)
Report a problemFND-0832593505
08HumanNon-randomized trialEfficacy outcome
In normally cycling women receiving goserelin, two had estradiol above 75 pmol/L during GnRH test C.
In plain wordsIn normally cycling women receiving goserelin, two had estradiol above 75 pmol/L during GnRH test C.
Peptide
Goserelin
Outcome
Not applicableEstradiol above suppression threshold during GnRH test C
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Patients with estradiol above 75 pmol/L
2 patients
goserelin, test C
Estradiol threshold
75 pmol/L
test C
Source sentences
Summary
Finally, individual E2 levels during test C were greater than 75 pmol/L in only two patients of group G, who also reported vaginal spotting.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
goserelin (group G; 3.6 mg, sc, every 28 days)
Report a problemFND-0832593508
09HumanNon-randomized trialSafety outcome
In normally cycling women receiving goserelin, the two patients with estradiol above 75 pmol/L during test C also reported vaginal spotting.
In plain wordsIn normally cycling women receiving goserelin, the two patients with estradiol above 75 pmol/L during test C also reported vaginal spotting.
Peptide
Goserelin
Outcome
Not applicableVaginal spotting
Study
n = 10
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3.6 mg every 28 days · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Patients reporting vaginal spotting
2 patients
goserelin, test C
Source sentences
Summary
Finally, individual E2 levels during test C were greater than 75 pmol/L in only two patients of group G, who also reported vaginal spotting.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
goserelin (group G; 3.6 mg, sc, every 28 days)
Report a problemFND-0832593509
10HumanNon-randomized trialEfficacy outcome
In normally cycling women with male-related infertility or benign reproductive disorders, one leuprorelin recipient had estradiol above 75 pmol/L during test B.
In plain wordsIn normally cycling women with male-related infertility or benign reproductive disorders, one leuprorelin recipient had estradiol above 75 pmol/L during test B.
Peptide
Leuprolide
Outcome
Not applicableEstradiol above suppression threshold during test B
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg every 28 days · intramuscularAs given in this study (human).
Measurements
Patients above estradiol threshold
1 patient
leuprorelin during test B
Estradiol
> 75 pmol/L
leuprorelin recipient during test B
Source sentences
Summary
In GnRH test B, while the mean estradiol (E2) level was less than 75 pmol/L (< 20 pg/mL) in all group B subjects, individual E2 levels were greater than 75 pmol/L in five patients receiving depot GnRH-A (two in group G, one in L, and two in T).
3 context sentences(design, population, supporting numbers)
Summary · context
GnRH tests (100 micrograms, iv) were performed before treatment (cycle day 7; test A) and on treatment days 57 (i.e. 1 day after the third depot GnRH-A; test B) and 84 (i.e. 28 days after the third depot GnRH-A; test C).
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
leuprorelin (group L; 3.75 mg, im, every 28 days),
Report a problemFND-0832593511

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In normally cycling women, the immunoreactive LH response to a GnRH test was profoundly suppressed during treatment with all four GnRH analogues tested (buserelin, goserelin, leuprorelin and triptorelin).
In plain wordsIn women, the LH response to a GnRH test was strongly suppressed during treatment with all four GnRH analogues tested, triptorelin included.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGnRH-stimulated immunoreactive LH
Study
n = 40
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Profound suppression of the iLH response to the GnRH test occurred in all subjects during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, we elected to study 40 normally cycling women with male-related infertility or benign reproductive disorders; each group of 10 subjects received a different GnRH-A for 3 months:
Summary · context
and triptorelin (group T; 3.75 mg, im, every 28 days).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0832593501

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 4Current
27 Oct 2026, 16:37 UTC
The same notice was added 2 times, first on 27 Oct 2026, 16:35 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC